SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Hansson Oskar) ;mspu:(article)"

Sökning: WFRF:(Hansson Oskar) > Tidskriftsartikel

  • Resultat 1-10 av 559
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Golman, Klaes, et al. (författare)
  • 13C-angiography.
  • 2002
  • Ingår i: Academic Radiology. - 1878-4046. ; 9:Suppl 2, s. 507-510
  • Tidskriftsartikel (refereegranskat)
  •  
2.
  •  
3.
  • Hansson, Karl, 1985, et al. (författare)
  • Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease
  • 2019
  • Ingår i: Clinical Mass Spectrometry. - : Elsevier BV. - 2376-9998. ; 14, s. 74-82
  • Tidskriftsartikel (refereegranskat)abstract
    • Cerebrospinal fluid (CSF) tau and phospho-tau are well established biomarkers of Alzheimer's disease. While these measures are conventionally referred to as 'total tau' (T-tau) and 'phospho-tau' (P-tau), several truncated and modified tau forms exist that may relay additional diagnostic information. We evaluated the diagnostic performance of an endogenous tau peptide in CSF, tau 175-190, in the phosphorylated and non-phosphorylated state. A liquid chromatography-mass spectrometry (LC-MS) method was established to measure these peptides in CSF and was used to analyze two independent clinical cohorts; the first cohort included patients with Alzheimer's disease (AD, n = 15), Parkinson's disease (PD, n = 15), progressive supranuclear palsy (PSP, n = 15), and healthy controls (n = 15), the second cohort included AD patients (n = 16), and healthy controls (n = 24). In both cohorts T-tau and P-tau concentrations were determined by immunoassay. While tau 175-190 and P-tau 175-190 did not differentiate the study groups, the separation of AD and controls by T-tau (area under the ROC Curve (AUC) = 95%) and P-tau (AUC = 92%) was improved when normalizing the ELISA measurements to the concentrations of the endogenous peptides: T-tau/tau 175-190 (AUC = 100%), P-tau/P-tau 175-190 (AUC = 95%). The separation between patients and controls by T-tau (AUC = 88%) and P-tau (AUC = 82%) was similarly improved in the second cohort by taking the ratios of T-tau/tau 175-190 (AUC = 97%) and P-tau/P-tau 175-190 (AUC = 98%). In conclusion, our results suggest that the performance of the AD biomarkers T-tau and P-tau could be improved by normalizing their measurements to the endogenous peptides tau 175-190 and P-tau 175-190, possibly because these endogenous tau peptides serve to normalize for physiological, and disease-independent, secretion of tau from neurons to the extracellular space and the CSF. Finally, the observations made here add to the general applicability of mass spectrometry as a tool for rapid identification and accurate quantification of biomarker candidates. (C) 2019 The Association for Mass Spectrometry: Applications to the Clinical Lab (MSACL). Published by Elsevier B.V. All rights reserved.
  •  
4.
  • Skillbäck, Tobias, et al. (författare)
  • A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease
  • 2017
  • Ingår i: Scientific Reports. - : Springer Science and Business Media LLC. - 2045-2322. ; 7
  • Tidskriftsartikel (refereegranskat)abstract
    • We present a new, quantification-driven proteomic approach to identifying biomarkers. In contrast to the identification-driven approach, limited in scope to peptides that are identified by database searching in the first step, all MS data are considered to select biomarker candidates. The endopeptidome of cerebrospinal fluid from 40 Alzheimer's disease (AD) patients, 40 subjects with mild cognitive impairment, and 40 controls with subjective cognitive decline was analyzed using multiplex isobaric labeling. Spectral clustering was used to match MS/MS spectra. The top biomarker candidate cluster (215% higher in AD compared to controls, area under ROC curve = 0.96) was identified as a fragment of pleiotrophin located near the protein's C-terminus. Analysis of another cohort (n = 60 over four clinical groups) verified that the biomarker was increased in AD patients while no change in controls, Parkinson's disease or progressive supranuclear palsy was observed. The identification of the novel biomarker pleiotrophin 151-166 demonstrates that our quantification-driven proteomic approach is a promising method for biomarker discovery, which may be universally applicable in clinical proteomics.
  •  
5.
  • Ackum, Susanne, et al. (författare)
  • Vi tar fram en handfast plan för en omstart av Sverige
  • 2020
  • Ingår i: Dagens Nyheter. - 1101-2447. ; :27 april
  • Tidskriftsartikel (populärvet., debatt m.m.)abstract
    • Det är /.../ fullt möjligt att tänka strategiskt och systematiskt även i brinnande kris. Omstartskommissionen hoppas kunna bidra till fokus, analys och konkreta policyförslag för att stödja Sveriges långsiktiga inriktning. Vi kommer att under våren och sommaren anordna seminarier och hearings om vårt arbete, delrapporter ska läggas fram – och när budgetarbetet börjar och Riksdagen öppnar, vill vi kunna bidra med en rejäl och handfast plan för hur vi omstartar Sverige.
  •  
6.
  • Aguillon, David, et al. (författare)
  • Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease
  • 2023
  • Ingår i: Alzheimer's and Dementia. - : Wiley. - 1552-5260 .- 1552-5279. ; 19:6, s. 2585-2594
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction: Plasma-measured tau phosphorylated at threonine 217 (p-tau217) is a potential non-invasive biomarker of Alzheimer's disease (AD). We investigated whether plasma p-tau217 predicts subsequent cognition and positron emission tomography (PET) markers of pathology in autosomal dominant AD. Methods: We analyzed baseline levels of plasma p-tau217 and its associations with amyloid PET, tau PET, and word list delayed recall measured 7.61 years later in non-demented age- and education-matched presenilin-1 E280A carriers (n = 24) and non-carrier (n = 20) family members. Results: Carriers had higher plasma p-tau217 levels than non-carriers. Baseline plasma p-tau217 was associated with subsequent amyloid and tau PET pathology levels and cognitive function. Discussion: Our findings suggest that plasma p-tau217 predicts subsequent brain pathological burden and memory performance in presenilin-1 E280A carriers. These results provide support for plasma p-tau217 as a minimally invasive diagnostic and prognostic biomarker for AD, with potential utility in clinical practice and trials. Highlights: Non-demented presenilin-1 E280A carriers have higher plasma tau phosphorylated at threonine 217 (p-tau217) than do age-matched non-carriers. Higher baseline p-tau217 is associated with greater future amyloid positron emission tomography (PET) pathology burden. Higher baseline p-tau217 is associated with greater future tau PET pathology burden. Higher baseline p-tau217 is associated with worse future memory performance.
  •  
7.
  • Ahmad, Shahzad, et al. (författare)
  • CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers
  • 2020
  • Ingår i: Scientific Reports. - : Springer Science and Business Media LLC. - 2045-2322. ; 10:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Many Alzheimer’s disease (AD) genes including Apolipoprotein E (APOE) are found to be expressed in blood-derived macrophages and thus may alter blood protein levels. We measured 91 neuro-proteins in plasma from 316 participants of the Rotterdam Study (incident AD = 161) using Proximity Extension Ligation assay. We studied the association of plasma proteins with AD in the overall sample and stratified by APOE. Findings from the Rotterdam study were replicated in 186 AD patients of the BioFINDER study. We further evaluated the correlation of these protein biomarkers with total tau (t-tau), phosphorylated tau (p-tau) and amyloid-beta (Aβ) 42 levels in cerebrospinal fluid (CSF) in the Amsterdam Dementia Cohort (N = 441). Finally, we conducted a genome-wide association study (GWAS) to identify the genetic variants determining the blood levels of AD-associated proteins. Plasma levels of the proteins, CDH6 (β = 0.638, P = 3.33 × 10−4) and HAGH (β = 0.481, P = 7.20 × 10−4), were significantly elevated in APOE ε4 carrier AD patients. The findings in the Rotterdam Study were replicated in the BioFINDER study for both CDH6 (β = 1.365, P = 3.97 × 10−3) and HAGH proteins (β = 0.506, P = 9.31 × 10−7) when comparing cases and controls in APOE ε4 carriers. In the CSF, CDH6 levels were positively correlated with t-tau and p-tau in the total sample as well as in APOE ε4 stratum (P < 1 × 10−3). The HAGH protein was not detected in CSF. GWAS of plasma CDH6 protein levels showed significant association with a cis-regulatory locus (rs111283466, P = 1.92 × 10−9). CDH6 protein is implicated in cell adhesion and synaptogenesis while HAGH protein is related to the oxidative stress pathway. Our findings suggest that these pathways may be altered during presymptomatic AD and that CDH6 and HAGH may be new blood-based biomarkers.
  •  
8.
  • Ahmadi, Khazar, et al. (författare)
  • Fixel-Based Analysis Reveals Tau-Related White Matter Changes in Early Stages of Alzheimer’s Disease
  • 2024
  • Ingår i: Journal of Neuroscience. - 0270-6474. ; 44:18
  • Tidskriftsartikel (refereegranskat)abstract
    • Several studies have shown white matter (WM) abnormalities in Alzheimer’s disease (AD) using diffusion tensor imaging (DTI). Nonetheless, robust characterization of WM changes has been challenging due to the methodological limitations of DTI. We applied fixel-based analyses (FBA) to examine microscopic differences in fiber density (FD) and macroscopic changes in fiber cross-section (FC) in early stages of AD (N = 393, 212 females). FBA was also compared with DTI, free-water corrected (FW)-DTI and diffusion kurtosis imaging (DKI). We further investigated the correlation of FBA and tensor-derived metrics with AD pathology and cognition. FBA metrics were decreased in the entire cingulum bundle, uncinate fasciculus and anterior thalamic radiations in Aβ-positive patients with mild cognitive impairment compared to control groups. Metrics derived from DKI, and FW-DTI showed similar alterations whereas WM degeneration detected by DTI was more widespread. Tau-PET uptake in medial temporal regions was only correlated with reduced FC mainly in the parahippocampal cingulum in Aβ-positive individuals. This tau-related WM alteration was also associated with impaired memory. Despite the spatially extensive between-group differences in DTI-metrics, the link between WM and tau aggregation was only revealed using FBA metrics implying high sensitivity but low specificity of DTI-based measures in identifying subtle tau-related WM degeneration. No relationship was found between amyloid load and any diffusion-MRI measures. Our results indicate that early tau-related WM alterations in AD are due to macrostructural changes specifically captured by FBA metrics. Thus, future studies assessing the effects of AD pathology in WM tracts should consider using FBA metrics.
  •  
9.
  • Ahmadi, Khazar, et al. (författare)
  • Gray matter hypoperfusion is a late pathological event in the course of Alzheimer's disease
  • 2023
  • Ingår i: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. - 1559-7016. ; 43:4, s. 565-580
  • Tidskriftsartikel (refereegranskat)abstract
    • Several studies have shown decreased cerebral blood flow (CBF) in Alzheimer's disease (AD). However, the role of hypoperfusion in the disease pathogenesis remains unclear. Combining arterial spin labeling MRI, PET, and CSF biomarkers, we investigated the associations between gray matter (GM)-CBF and the key mechanisms in AD including amyloid-β (Aβ) and tau pathology, synaptic and axonal degeneration. Further, we applied a disease progression modeling to characterize the temporal sequence of different AD biomarkers. Lower perfusion was observed in temporo-occipito-parietal cortex in the Aβ-positive cognitively impaired compared to both Aβ-negative and Aβ-positive cognitively unimpaired individuals. In participants along the AD spectrum, GM-CBF was associated with tau, synaptic and axonal dysfunction, but not Aβ in similar cortical regions. Axonal degeneration was further associated with hypoperfusion in cognitively unimpaired individuals. Disease progression modeling revealed that GM-CBF disruption Followed the abnormality of biomarkers of Aβ, tau and brain atrophy. These findings indicate that tau tangles and neurodegeneration are more closely connected with GM-CBF changes than Aβ pathology. Although subjected to the sensitivity of the employed neuroimaging techniques and the modeling approach, these findings suggest that hypoperfusion might not be an early event associated with the build-up of Aβ in preclinical phase of AD.
  •  
10.
  • Andersson, Carl-Henrik, et al. (författare)
  • A Genetic Variant of the Sortilin 1 Gene isAssociated with Reduced Risk ofAlzheimer's Disease
  • 2016
  • Ingår i: Journal of Alzheimer's Disease. - 1387-2877 .- 1875-8908. ; 53:4, s. 1353-1363
  • Tidskriftsartikel (refereegranskat)abstract
    • Alzheimer's disease (AD) is a neurodegenerative disorder represented by the accumulation of intracellular tau protein and extracellular deposits of amyloid-β (Aβ) in the brain. The gene sortilin 1 (SORT1) has previously been associated with cardiovascular disease in gene association studies. It has also been proposed to be involved in AD pathogenesis through facilitating Aβ clearance by binding apoE/Aβ complexes prior to cellular uptake. However, the neuropathological role of SORT1 in AD is not fully understood. To evaluate the associations between gene variants of SORT1 and risk of AD, we performed genetic analyses in a Swedish case-control cohort. Ten single nucleotide polymorphisms (SNPs), covering the whole SORT1 gene, were selected and genotyped in 620 AD patients and 1107 controls. The SNP rs17646665, located in a non-coding region of the SORT1 gene, remained significantly associated with decreased risk of AD after multiple testing (pc=0.0061). In addition, other SNPs were found to be nominally associated with risk of AD, as well as altered cognitive function and the CSF biomarker Aβ42, but these associations did not survive correction for multiple testing. The fact that SORT1 has been strongly associated with risk of cardiovascular disease is intriguing as cardiovascular disease is also regarded as a risk factor for AD. Finally, increased knowledge about SORT1 function has a potential to increase our understanding of APOE, the strongest risk factor for AD.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 559
Typ av publikation
Typ av innehåll
refereegranskat (553)
populärvet., debatt m.m. (5)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Hansson, Oskar (537)
Stomrud, Erik (159)
Blennow, Kaj, 1958 (153)
Zetterberg, Henrik, ... (140)
Palmqvist, Sebastian (140)
Janelidze, Shorena (134)
visa fler...
Minthon, Lennart (103)
Mattsson-Carlgren, N ... (97)
Smith, Ruben (75)
Ossenkoppele, Rik (71)
Strandberg, Olof (69)
van Westen, Danielle (64)
Blennow, Kaj (58)
Zetterberg, Henrik (50)
Londos, Elisabet (42)
Mattsson, Niklas (39)
Leuzy, Antoine (38)
Hall, Sara (35)
Nägga, Katarina (28)
Ashton, Nicholas J. (25)
Insel, Philip S (25)
Andreasson, Ulf, 196 ... (24)
Nilsson, Markus (21)
Brundin, Patrik (21)
Wallin, Anders, 1950 (20)
Teunissen, Charlotte ... (20)
Jögi, Jonas (20)
Scheltens, Philip (19)
Mattsson, Niklas, 19 ... (19)
Pereira, Joana B. (18)
Rabinovici, Gil D (18)
Dage, Jeffrey L. (16)
van der Flier, Wiesj ... (16)
Hampel, Harald (16)
Ohlsson, Tomas (16)
Spotorno, Nicola (15)
La Joie, Renaud (15)
Westman, Eric (14)
Salvadó, Gemma (14)
Gobom, Johan (14)
Cullen, Nicholas C (14)
Bateman, Randall J (14)
Vogel, Jacob W (14)
Brinkmalm, Gunnar (13)
Ewers, Michael (13)
Portelius, Erik, 197 ... (12)
Groot, Colin (12)
Frisoni, Giovanni B. (12)
Lindqvist, Daniel (12)
Binette, Alexa Piche ... (12)
visa färre...
Lärosäte
Lunds universitet (528)
Göteborgs universitet (236)
Karolinska Institutet (94)
Linköpings universitet (39)
Uppsala universitet (24)
Umeå universitet (10)
visa fler...
Högskolan Kristianstad (8)
Örebro universitet (6)
Stockholms universitet (5)
Högskolan i Skövde (3)
Malmö universitet (2)
Chalmers tekniska högskola (2)
Linnéuniversitetet (2)
Sveriges Lantbruksuniversitet (2)
Kungliga Tekniska Högskolan (1)
Mittuniversitetet (1)
Karlstads universitet (1)
IVL Svenska Miljöinstitutet (1)
visa färre...
Språk
Engelska (550)
Svenska (9)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (547)
Naturvetenskap (12)
Samhällsvetenskap (6)
Teknik (4)
Lantbruksvetenskap (2)
Humaniora (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy